Trends in antineoplastic receipt after medicare payment reform: Implications for future oncology payment design

Our results indicate that providers responded to reimbursement changes after the MMA by increasing use of newly approved agents, but the magnitude of the response was small and limited to individuals diagnosed with Stage IV disease.